treatment as usual

PreclinicalSmall molecule

treatment as usual is one of 194 small molecule programs targeting Postnatal Depression. It is currently in Preclinical.

Indications

Total Trials

Active Trials

193

Competitors

Pipeline

Status by Indication[3][1]

Indication

Postnatal DepressionNot yet recruiting

Bipolar I DisorderActive, not recruiting

ThyroiditisActive, not recruiting

Chronic PainActive, not recruiting

PsychosisActive, not recruiting

IrritabilityActive, not recruiting

Major Depressive DisorderActive, not recruiting

Generalized Anxiety DisorderActive, not recruiting

Treatment Resistant DepressionActive, not recruiting

Non-Suicidal Self-Injury (NSSI)Not yet recruiting

Postnatal DepressionPreclinical

Not yet recruiting

Bipolar I DisorderPreclinical

Active, not recruiting

ThyroiditisPreclinical

Active, not recruiting

Chronic PainPreclinical

Active, not recruiting

PsychosisPreclinical

Active, not recruiting

IrritabilityPreclinical

Active, not recruiting

Major Depressive DisorderPreclinical

Active, not recruiting

Generalized Anxiety DisorderPreclinical

Active, not recruiting

Treatment Resistant DepressionPreclinical

Active, not recruiting

Non-Suicidal Self-Injury (NSSI)Preclinical

Not yet recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

120 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

12 2

Ketalar

Boehringer Ingelheim

Phase 3

3 3

Sunosi

AAxsome Therapeutics, Inc.

Phase 3

1 4

Clozaril

LLife Extension Foundation Inc.

Phase 3

1 5

Lithobid

SSolvay Pharmaceuticals

Phase 3

1 6

Psilocybin

COMPASS Pathways

Phase 3

11 7

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

2 8

Aticaprant

Johnson & Johnson

Phase 3

4 9

Selective Serotonin Reuptake Inhibitor

Johnson & Johnson

Phase 3

2 10

Azetukalner

XXenon Pharmaceuticals Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

N/ANot yet recruiting

Postnatal Depression

NCT06990802

Q4 2028

Post-ApprovalRecruiting

Schizophrenia

NCT05208190

PreclinicalNot yet recruiting

Non-Suicidal Self-Injury (NSSI)

NCT07683234

Q1 2031

Phase 2Not yet recruiting

Idiopathic Pulmonary Fibrosis

NCT07674745

Clinical

Trials by Indication[1]

Schizophrenia4 trials

Culturally Adapted Cognitive Behavior Therapy Based Guided Self-help Manual for Schizophrenia Spectrum Disorder

Completed·UUniversity of the Punjab·N/A·NCT06895421·170 enrolled

Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual

Completed·—·Phase 4·NCT00498550·31 enrolled

Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial

Completed·—·Phase 3·NCT03955549·99 enrolled

Show 1 more trial

Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

Recruiting·NNew York State Psychiatric Institute·Phase 4·NCT05208190·280 enrolled

Bipolar Disorder2 trials

Culturally Adapted Psychoeducation (CaPE) for Bipolar Disorders in Nigeria

Unknown status·—·N/A·NCT05721196·120 enrolled

Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?

Completed·VVanderbilt University·Phase 4·NCT00571688·50 enrolled

Idiopathic Pulmonary Fibrosis2 trials

Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT03286556·82 enrolled

Study of Therapeutic Plasma Exchange, Rituximab, and Intravenous Immunoglobulin for Progressive Idiopathic Pulmonary Fibrosis (STRIVE II)

Not yet recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT07674745·52 enrolled

Treatment Resistant Depression1 trial

Neurofeedback In Treatment Resistant Depression

Terminated·YYeungnam University Hospital·N/A·NCT04078438·70 enrolled

Trauma1 trial

Identity Oriented Psychotrauma Therapy on Hashimoto in Adults

Completed·—·N/A·NCT04600349·70 enrolled

19 more indications

Thyroiditis1 trial

Eye Movement Desensitization and Reprocessing on Autoimmune Thyroiditis in Adults

Completed·—·N/A·NCT04472988·91 enrolled

Chronic pain1 trial

Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach

Unknown status·FFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta·N/A·NCT04859374·35 enrolled

Long COVID Syndrome1 trial

Prevention of Long Covid Syndrome

Completed·UUniversity of Cagliari·N/A·NCT05793736·17 enrolled

Generalized Anxiety Disorder1 trial

Digital Interventions As an Add-on Tool in Generalized Anxiety Disorder Treatment

Completed·HHospital de Clinicas de Porto Alegre·N/A·NCT05375851·60 enrolled

Treatment1 trial

Trial to Evaluate Efficacy of Pharmacogenetic Information Obtained With NEUROPHARMAGEN in Treatment of MDD Patients

Completed·AAB Biotics, SA·Phase 3·NCT02529462·521 enrolled

Bipolar I Disorder1 trial

Pilot Study of Cognitive Behavioral Therapy for Anxiety and Bipolar I Disorder

Completed·MMassachusetts General Hospital·N/A·NCT01892306·34 enrolled

Depression1 trial

Optimization of Diagnosis and Treatment of Depression Based on Multidimensional Clinical Assessment Classification

Unknown status·SShanghai Mental Health Center·N/A·NCT04528628·960 enrolled

Irritability1 trial

RESist Against Irritability Superiority Trial

Recruiting·UUniversity Hospital, Montpellier·N/A·NCT05528926·270 enrolled

Psychosis1 trial

A Rater-blinded RCT to Compare Effectiveness of EMDR vs TAU in Patients With First Episode Psychosis and History of Psychological Trauma

Unknown status·PParc de Salut Mar·N/A·NCT03991377·71 enrolled

Transdiagnostic1 trial

Effectiveness of a Transdiagnostic Internet-based Treatment for Emotional Disorders

Completed·UUniversitat Jaume I·N/A·NCT02345668·200 enrolled

Adolescent1 trial

Guideline vs Usual Treatment in Schizophrenic Adolescents

Completed·HHospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico·N/A·NCT02573701·91 enrolled

Postnatal Depression1 trial

Clinical and Cost-effectiveness of Learning Through Play Plus Culturally Adapted Cognitive Behaviour Therapy for Postnatal Depression in Nigeria

Not yet recruiting·—·N/A·NCT06990802·432 enrolled

Major Depressive Disorder1 trial

Cognitive Behavior Therapy Among Patients With Major Depressive Disorder-Multiple Episodes.

Not yet recruiting·GGovernment College University Faisalabad·N/A·NCT07300527·80 enrolled

Medication1 trial

Clinical Utility of Pharmacogenomics of Psychotropic Medications

Withdrawn·OOregon Health and Science University·Phase 4·NCT03907124

Effectiveness1 trial

EXHIT ENTRE Comparative Effectiveness Trial

Completed·GGavin Bart·Phase 2/3·NCT04345718·344 enrolled

Mindfulness1 trial

Mindfulness-Based Cognitive Therapy: Efficacy and fMRI-based Response Predictors in a Group of OCD Patients

Unknown status·CCorporacion Parc Tauli·N/A·NCT03128749·60 enrolled

Pulpitis1 trial

Evaluatıon of the Effect of Pulpotomy Treatments wıth dıfferent bıomaterıals on postoperatıve paın ın Permanent Molars

Completed·TTC Erciyes University·Approved·NCT06784622·58 enrolled

Bipolar Depression1 trial

A Randomized Controlled Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression

Completed·TThe University of Texas Health Science Center, Houston·Phase 2·NCT06229977·34 enrolled

Non-suicidal Self-injury (NSSI)1 trial

A Novel Digital Psychotherapy Intervention for Non-Suicidal Self-Injury in Adolescents: A Randomized Controlled Trial

Not yet recruiting·TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine·Preclinical·NCT07683234·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 29 trial records for treatment as usual. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — treatment as usual compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for treatment as usual. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AB Biotics, SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAB Biotics, SA

treatment as usual

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2028

Q1 2031

Trials by Indication[1]

Schizophrenia4 trials

Bipolar Disorder2 trials

Idiopathic Pulmonary Fibrosis2 trials

Treatment Resistant Depression1 trial

Trauma1 trial

Thyroiditis1 trial

Chronic pain1 trial

Long COVID Syndrome1 trial

Generalized Anxiety Disorder1 trial

Treatment1 trial

Bipolar I Disorder1 trial

Depression1 trial

Irritability1 trial

Psychosis1 trial

Transdiagnostic1 trial

Adolescent1 trial

Postnatal Depression1 trial

Major Depressive Disorder1 trial

Medication1 trial

Effectiveness1 trial

Mindfulness1 trial

Pulpitis1 trial

Bipolar Depression1 trial

Non-suicidal Self-injury (NSSI)1 trial

References

Drug Info

Quick Facts

Related News